Journal article
Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings
Addiction, Vol.114(6), pp.1026-1034
06/2019
Metrics
14 File views/ downloads
10 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Abstract
Background and aims: Pregabalin is a gamma‐aminobutyric acid (GABA) analogue, used to treat neuropathic pain and epilepsy. Pregabalin was registered in Australia in 2005, and subsidized publically in 2013. We aimed to describe Australian patterns of pregabalin use and intentional poisoning, and identify people potentially at high risk of misuse. Design and setting: Population‐based retrospective cohort study of dispensings in the 10% sample of Australian Pharmaceutical Benefits Scheme (July 2012–February 2017); intentional poisoning calls to New South Wales Poisons Information Centre (NSWPIC) (2004–2016); intentional poisonings in two Australian toxicology service databases; and poisoning fatalities in NSW coronial records (2005–2016). Participants: A total of 122 572 people dispensed pregabalin, people with intentional pregabalin overdoses managed by NSWPIC and the toxicology services and pregabalin‐associated deaths referred to the NSW coroner. Measurements: Trends in dispensing, poisoning, death; demographics and patient characteristics, proportion of users at high risk of misuse (latent class analysis, LCA) and characteristics of high‐risk users. Findings: Pregabalin dispensing increased by 73 424 per year [95% confidence interval (CI) = 61726–85 121 P < 0.001] between 2013 and 2016. NSWPIC received 1158 reports of intentional pregabalin poisonings, with a 53.8% increase per year, 2005–2016 (95% CI = 44.0–64.2%, P < 0.001). We identified 88 pregabalin‐associated deaths, 57.8% yearly increase (95% CI = 30.0–91.6%, P < 0.001). Patients overdosing on pregabalin commonly co‐ingested opioids, benzodiazepines and illicit drugs, and had high rates of psychiatric and substance use comorbidities; 14.7% of pregabalin users were classed by the LCA as at high risk of misuse, and were more likely to be younger, male, co‐prescribed benzodiazepines or opioids, have more individual prescribers and higher pregabalin strengths dispensed. Conclusions: There has been a dramatic increase in pregabalin use, poisonings and deaths in Australia since it became subsidized publicly in 2013. One in seven Australians dispensed pregabalin appears to be at high risk of misuse.
Details
- Title
- Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings
- Creators
- Rose Cairns (Corresponding Author) - Children's Hospital at WestmeadAndrea L Schaffer (Author) - University of New South WalesNicole Ryan (Author) - University of Newcastle AustraliaSallie-Anne Pearson (Author) - University of New South WalesNicholas A Buckley (Author) - Children's Hospital at Westmead
- Publication Details
- Addiction, Vol.114(6), pp.1026-1034
- Publisher
- Wiley-Blackwell
- Grant note
- Centre of Research Excellence in Medicines and Ageing. Grant Number: 1060407 National Health and Medical Research Council (NHMRC). Grant Number: 1055176
- Identifiers
- 991013151813702368
- Copyright
- © 2018 Society for the Study of Addiction
- Academic Unit
- Faculty of Health
- Language
- English
- Resource Type
- Journal article